BioNxt Solutions Inc. (CSE:BNXT)

Market Cap	105.69M
Revenue (ttm)	22.85K
Net Income (ttm)	-5.71M
Shares Out	117.44M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	578,092
Average Volume	167,704
Open	1.0000
Previous Close	1.0000
Day's Range	0.8100 - 1.0000
52-Week Range	0.1800 - 1.1000
Beta	1.54
RSI	71.69
Earnings Date	Aug 27, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BNXT

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.